QB3 Webinar: Sonja Schrepfer, Sana Biotechnology. “The Future of Stem Cell Therapy: Hypoimmune Cell Products”

Induced pluripotent stem cells (iPSCs) hold great potential as therapies to repair damaged tissue or replace cell types missing due to genetic defects. However, even iPSCs derived from a patient can mutate in culture, causing immune rejection when they are re-transplanted. Being able to control immune rejection is key to using iPSCs as theraputics. The end goal, for safety and efficiency, is a gene-engineered, hypoimmunogenic, universal cell product. In this talk, Sonja Schrepfer of Sana Biotechnologies will describe how she and Sana are working to ensure that transplanted iPSCs survive both T cell and innate immune surveillance.